Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Infectious Diseases

    Children Infected with a Mild Case of COVID-19 Can Still Develop Long COVID Symptoms

    By Global Biodefense StaffAugust 10, 2022
    Will Henjum, a 7 year old boy, receives the first dose of Pfizer-BioNTech pediatric COVID-19 vaccine. Credit: Inkyeong Yun
    Share
    Facebook LinkedIn Reddit Email

    While research has revealed that children and adults hospitalized with COVID-19 are more susceptible to developing long COVID symptoms, a new study by researchers at UTHealth Houston found that children infected with COVID-19, but not hospitalized, still experienced long COVID symptoms up to three months past infection.

    Researchers examined data from volunteers across the state of Texas between the ages of 5 and 18 who were enrolled in the Texas CARES survey, which began in October of 2020 with the goal of assessing COVID-19 antibody status over time among a population of adults and children in Texas.

    Data for this study was collected before and after the vaccine rollout and during the waves of the Delta and Omicron variants.

    “We were interested in understanding if children impacted with an acute or severe infection of COVID-19 would go on to have persisting symptoms, or what we call long COVID,” said Sarah Messiah, PhD, MPH, first author of the study and professor of epidemiology, human genetics, and environmental sciences and director of the Center for Pediatric Population Health at UTHealth School of Public Health-Dallas. “This particular study is unique as the first population-based study in literature to report on prevalence of long COVID in children who have not been hospitalized with COVID-19.”

    A total of 82 pediatric volunteers (4.8% of the total 1,813) reported having long COVID symptoms – 1.5% showed symptoms that lasted between four and 12 weeks, including loss of taste and smell, fatigue, and cough. An additional 3.3% reported that symptoms such as loss of taste and smell, cough, and difficulty breathing persisted for longer than 12 weeks.

    “From this information we wanted to know, ‘What would put a child more at risk for long COVID and who is more susceptible to this?’ When we looked at risk factors of those who reported symptoms past 12 weeks, we found that children who were unvaccinated and who had obesity had a higher chance of developing long COVID. These findings are consistent with other literature that found children and adults who have comorbid health conditions and are unvaccinated are at a higher risk of being hospitalized for the virus,” Messiah said.

    Additionally, researchers found that children infected with COVID-19 before the emergence of the Delta variant were more at risk of developing long COVID. “If you had COVID-19 earlier in the pandemic, you were more at risk for longer symptoms. With Delta and Omicron, we did see a lot of children who ended up hospitalized, but their symptoms were less severe, and our results show they were also less likely to report persistent symptoms too,” Messiah said.  

    The results of the Texas CARES study, Messiah said, is important because it highlights the presence of non-hospitalized youth who may also experience persistent long COVID symptoms after infection.

    “There may be a perception that one needs to be hospitalized to have long COVID, and that is not what we found. I encourage parents to still take caution and get their child vaccinated against COVID-19, because we now know that it will decrease the risk of infection and long COVID,” she said.

    Source: Adapted from the University of Texas Health Science Center at Houston

    Comparison of Persistent Symptoms Following SARS-CoV-2 Infection by Antibody Status in Nonhospitalized Children and Adolescents. The Pediatric Infectious Disease Journal, 1 August 2022.

    COVID-19 Long COVID Medicine-Health Pediatric Infectious Diseases SARS-CoV-2
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleMount Sinai Announces the Formation of Clinical-Stage Infectious Diseases Company CastleVax
    Next Article Many Children Hospitalized with COVID-19 or MIS-C Have Lingering Complications Months Later

    Related Stories

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    Healthcare Workers Express Outrage at Flawed CDC Mask Guidance

    September 18, 2023

    Mount Sinai to Lead Development of Pan-Coronavirus Vaccine Under New Federal Grant

    September 17, 2023

    New Research on Causes of Brain Swelling in Cerebral Malaria

    September 13, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.